-
Eli Lilly Tops Ests; Guides In Line - Analyst Blog
Thursday, January 27, 2011 - 11:31am | 813Eli Lilly (LLY) reported fourth quarter earnings per share of $1.11, a penny above the Zacks Consensus Estimate and 22% above the year-ago earnings of 91 cents. Fourth quarter results were driven by higher revenues and a lower tax rate. Fourth quarter revenues increased 4% to $6.2 billion,...
-
Cost Control Helps Amylin Cut Loss - Analyst Blog
Thursday, January 27, 2011 - 11:31am | 1270Amylin Pharmaceuticals (AMLN) reported a net loss of 8 cents per share in the fourth quarter of 2010, well below the Zacks Consensus Estimate and the year-ago loss of 32 cents. Full year 2010 loss came in at 94 cents, significantly below the Zacks Consensus Estimate of a loss of $1.26 and the...
-
Cost Control Helps Amylin Cut Loss - Analyst Blog
Thursday, January 27, 2011 - 11:15am | 1270Amylin Pharmaceuticals (AMLN) reported a net loss of 8 cents per share in the fourth quarter of 2010, well below the Zacks Consensus Estimate and the year-ago loss of 32 cents. Full year 2010 loss came in at 94 cents, significantly below the Zacks Consensus Estimate of a loss of $1.26 and the...
-
Covance in Tune with Zacks Est. - Analyst Blog
Thursday, January 27, 2011 - 11:01am | 628Covance (CVD) reported an EPS of 45 cents for the fourth quarter of fiscal 2010 compared with 64 cents of the year-ago quarter. However, considering some adjustments, the EPS came in at 56 cents, beating the Zacks Consensus Estimate of 53 cents. For fiscal 2010, the adjusted EPS was $2.15,...
-
Eli Lilly Tops Ests; Guides In Line - Analyst Blog
Thursday, January 27, 2011 - 10:45am | 813Eli Lilly (LLY) reported fourth quarter earnings per share of $1.11, a penny above the Zacks Consensus Estimate and 22% above the year-ago earnings of 91 cents. Fourth quarter results were driven by higher revenues and a lower tax rate. Fourth quarter revenues increased 4% to $6.2 billion,...
-
Covance in Tune with Zacks Est. - Analyst Blog
Thursday, January 27, 2011 - 10:30am | 628Covance (CVD) reported an EPS of 45 cents for the fourth quarter of fiscal 2010 compared with 64 cents of the year-ago quarter. However, considering some adjustments, the EPS came in at 56 cents, beating the Zacks Consensus Estimate of 53 cents. For fiscal 2010, the adjusted EPS was $2.15,...
-
Mylan's Subsidiary Obtains License for Promising HIV/AIDS Treatment
Thursday, January 27, 2011 - 10:12am | 77Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has signed an agreement with Tibotec Pharmaceuticals for a non-exclusive license to manufacture, market and distribute a generic version of the non-nucleoside reverse transcriptase inhibitor Rilpivirine...
-
China's Ministry of Commerce Grants Clearance for BMP Sunstone and Sanofi-aventis Subsidiary Merger
Thursday, January 27, 2011 - 10:03am | 101BMP Sunstone Corporation (Nasdaq: BJGP) announced today that China's Ministry of Commerce granted clearance for the transaction in which sanofi-aventis (NYSE: SNY) will acquire all outstanding shares of BMP Sunstone Corporation. The acquisition is structured as a merger of BMP Sunstone and a...
-
J.P. Morgan Decreases PT on Abbott Laboratories to $55 (ABT)
Thursday, January 27, 2011 - 9:55am | 191J.P. Morgan is out with its report on Abbott Laboratories (NYSE: ABT), decreasing its PT from $60 to $55. In a note to clients, J.P. Morgan writes, "Abbott reported in-line 4Q results Wednesday morning. EPS of $1.30 (+10%) was a penny above consensus and our forecast. Revenues of $9.968B were up 13...
-
DURECT Announces REMOXY New Drug Application Accepted by the FDA
Thursday, January 27, 2011 - 9:46am | 102DURECT Corporation (Nasdaq: DRRX) today reported that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for REMOXY by King Pharmaceuticals, Inc. (NYSE: KG) and the PDUFA goal date is June 23, 2011. REMOXY, based on DURECT's ORADUR®...
-
Benzinga's Top Downgrades (ANF, RSH, PJC, ABT)
Thursday, January 27, 2011 - 9:28am | 138Abercrombie & Fitch Company (NYSE: ANF) was downgraded by FBR Capital from "outperform" to "market perform." ANF's shares closed at $49.59 yesterday. Abercrombie & Fitch's trailing-twelve-month profit margin is 3.23%. Analysts at RBC Capital downgrade Radioshack Corporation (NYSE: RSH) from...
-
Making Use Of All Tools Available.
Thursday, January 27, 2011 - 9:26am | 1571Long time readers will know about some of the building blocks I believe in for portfolio construction which include a mix of different tools, a higher dividend than the S&P 500 (most of the time), building a portfolio at the sector level and a lot of foreign exposure. Every now and then I like...
-
Bristol-Myers Squibb Reports 47 Cent EPS (BMY)
Thursday, January 27, 2011 - 9:12am | 149New York, New York-based Bristol-Myers Squibb Company (NYSE: BMY) released financial results on Thursday morning. Bristol-Myers Squibb Company announced that its 4th quarter net earnings from continuing operations fell to $483 million, or 28 cents per share, down from $818 million, or 41 cents per...
-
Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance
Thursday, January 27, 2011 - 8:52am | 219Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2010. Financial results for 2010 and 2009 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with generally accepted accounting principles (...
-
J.P. Morgan Lowers ABT Target To $55 From $60
Thursday, January 27, 2011 - 8:39am | 22J.P. Morgan is lowering its PT on Abbott Laboratories (NYSE: ABT) to $55 from $60.